KTTA News and Press, Pasithea Therapeutics Corp. From 10/27/22

(NewsDirect) Learn More about Pasithea Therapeutics by gaining access to the latest research report When the world is focused on a global pandemic no one saw coming four years ago, the attention given to escalating diseases with no known cure can be hidden from the public consci...

MIAMI BEACH, Fla., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disor...

Condemns the Current Board’s Decision to Disregard Stockholder Feedback and Proceed with a Second Highly Dilutive Acquisition Within the Last Six Months Urges the Board to Act on Stockholder Feedback and Schedule the Special Meeting Without Further Delay Camac...

Palm Beach, FL –– October 12, 2022 – FinancialNewsMedia.com News Commentary – The COVID pandemic has not only had a negative effect on most markets but it has also spurred growth in several worldwide markets. The COVID-19 pandemic has impacted the who...

-- Expands CNS Product Portfolio with Addition of CIP-137401, a Macrocyclic, Next-Generation MEK Inhibitor -- Plans to File IND Application with the FDA to Enter the Clinic in 2H 2023 -- Plans to Initiate a Phase 1 Clinical Trial in the U.S. for Neurofibromatosis Type 1 ...

--News Direct-- People suffering from incurable neurological diseases such as multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS) hope new therapies and drugs will arrive sooner than later. A chronic and inflammatory neurodegenerative disease, MS affects 400,000 peop...

MIAMI BEACH, Fla., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research and development of new and effective treatments for central nervous system (C...

--News Direct-- Learn More about Pasithea Therapeutics by gaining access to the latest research report Vaccines that boost the body’s immune system against foreign proteins are different than those that are an inverse vaccine fighting an autoimmune disease. The la...

Urges the Company to Honor Stockholders’ Will and Hold the Special Meeting Without Further Delay Expresses Disappointment with the Board’s Entrenchment Tactics, Including Its Recent Decision to Appoint a Director Without Consulting Stockholders ...

MIAMI BEACH, Fla., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research and development of new and effective treatments for central nervous system (...